Biotech Stocks 2026: XBI, ARKG, LABU and the Sector Surge

Biotech is having one of its best runs in years. The SPDR S&P Biotech ETF (XBI) has returned +88.8% over the past twelve months. The ARK Genomic Revolution ETF (ARKG) is up +72.4% over the same period. The Direxion Daily S&P Biotech Bull 3X (LABU), a leveraged instrument, has returned +396.1%. These are not rounding errors. Something structural has shifted in how the market is pricing biotech risk, and understanding that shift matters more than chasing the headline numbers.

What Changed in 2026

For most of 2022 through 2024, biotech was a sector where capital went to die. Rising rates crushed the discounted cash flow math on pre-revenue drug developers. The XBI spent two years grinding sideways while the S&P 500 recovered. Then the calculus flipped.

Three forces converged. First, the rate environment stabilized enough to stop being an active headwind for long-duration assets. Second, M&A activity from large-cap pharma accelerated as pipelines thinned and patent cliffs loomed. Large acquirers need to buy growth; small and mid-cap biotech is where that growth lives. Third, AI-assisted drug discovery moved from a talking point to a demonstrable accelerant, compressing timelines on target identification and trial design in ways that are starting to show up in clinical readouts.

The ACCE Biotech Catalysts index captures this dynamic directly. Its current NAV sits at 1117.02, with concentrated positions in names that have genuine near-term catalysts rather than decade-long development timelines.

The Index Holdings Tell the Story

The ACCE Biotech Catalysts index is not a passive bet on the sector. Its top five positions, Vertex Pharmaceuticals (VRTX) at 22%, Sarepta Therapeutics (SRPT) at 19%, BioMarin Pharmaceutical (BMRN) at 18%, Eli Lilly (LLY) at 17%, and Regeneron Pharmaceuticals (REGN) at 15%, together account for 91% of the portfolio. Novo Nordisk (NVO) holds a 9% weight. Madrigal Pharmaceuticals (MDGL) sits at 0%, suggesting a recent trim or a position being built.

This concentration is intentional. Each of these names has a specific catalyst profile: Vertex with its pain franchise and CF dominance, Sarepta with its gene therapy pipeline, BioMarin with rare disease pricing power, Lilly with GLP-1 volume still expanding globally, and Regeneron with Dupixent label extensions still rolling through. These are not speculative bets. They are companies with approved products generating real cash flow, held because the market has not yet fully priced the next leg of their growth.

The contrast with the broader XBI is instructive. XBI holds roughly 150 names, including many pre-revenue developers. Its +88.8% one-year return reflects the full spectrum of the biotech recovery, from small-cap binary events to large-cap re-ratings. ARKG's +72.4% sits in the middle, with a genomics and precision medicine tilt that has benefited from the AI-in-drug-discovery narrative.

The Leverage Question: LABU

LABU's +396.1% one-year return demands a direct comment. This is a 3x leveraged daily-reset product. Returns of that magnitude over a twelve-month window are only possible when the underlying sector trends persistently in one direction with limited volatility drag. That is exactly what happened: biotech moved up steadily enough that the daily compounding worked in holders' favor rather than against them.

This will not always be the case. Leveraged ETFs are path-dependent instruments. A sector that chops sideways for six months, even if it ends flat, will destroy value in a 3x product through volatility decay. LABU's score of 97 reflects pure momentum, not fundamentals. The score breakdown shows only a Momentum reading; there is no Growth, Value, or Quality component to anchor it. Anyone treating LABU as a long-term holding rather than a tactical momentum vehicle is misreading what the instrument is.

Where the Risks Are Concentrated

The biotech rally has not been uniform. The ACCE alert feed this week flagged BridgeBio Pharma (BBIO) raising $933.9M in convertible preferred equity, a transaction that bolsters the balance sheet but introduces dilution risk and signals the company is not yet self-funding. That is a common pattern in mid-cap biotech: strong pipeline, insufficient cash generation, recurring capital raises that keep shareholders perpetually diluted.

AEVA Technologies (AEVA), while not a biotech name, illustrates a related dynamic that appears across high-growth sectors right now. Its CEO and CFO both sold shares near 52-week highs last week. Insider selling at highs, combined with a Quality score of just 13 and an ROE of -516.1%, is a pattern worth watching in any sector where momentum has run hard. Biotech is full of names with similar profiles: strong momentum scores, weak quality scores, and management teams that know exactly when to reduce exposure.

The Macro Backdrop for H2 2026

Biotech's sensitivity to macro conditions has not disappeared. It has just been dormant. The sector's performance in the back half of 2026 will depend heavily on whether the current rate environment holds, whether M&A activity sustains its pace, and whether any large clinical failures create a sentiment reset.

The GLP-1 story, anchored by Eli Lilly (LLY) and Novo Nordisk (NVO), both held in the ACCE Biotech Catalysts index, continues to expand into new indications including cardiovascular outcomes, sleep apnea, and metabolic liver disease. That pipeline breadth gives the large-cap end of the sector a growth runway that is relatively independent of macro conditions. The small-cap end, represented by the tail of the XBI, remains binary and rate-sensitive.

The ACCE Biotech Catalysts index's NAV of 1117.02 reflects a portfolio that has been deliberately positioned toward the large-cap, cash-generative end of the spectrum while retaining exposure to mid-cap names with near-term catalysts. That construction has worked. The question for the second half of 2026 is whether the M&A bid that has supported small and mid-cap valuations continues, or whether acquirers pause to digest recent deals.

The genomics and precision medicine segment, ARKG's core territory, has a longer runway than the current momentum suggests. Whole-genome sequencing costs have fallen by orders of magnitude over the past decade, and the clinical applications are only beginning to scale. The +72.4% one-year return in ARKG is partly a recovery from oversold levels and partly a genuine re-rating of what these technologies are worth at commercial scale. Both components are real, and separating them is the analytical work that determines whether the next twelve months look anything like the last twelve.